Literature DB >> 11442180

Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands.

J B Oostenbrink1, M P Rutten-van Mölken, T S Sluyter-Opdenoordt.   

Abstract

PURPOSE: To estimate resource use and costs associated with the diagnosis and treatment of glaucoma and ocular hypertension in the Netherlands in 1996 and to determine how costs differed between patients, diagnoses, and hospitals. PATIENTS AND METHODS: Patient characteristics and glaucoma-related resource use were collected for 500 patients with glaucoma or ocular hypertension from the medical records of 10 hospitals. Costs were calculated by multiplying the health care resource use of each patient with actual unit costs. Multiple least-squares regression was used to analyze the relationship between costs and patient characteristics, diagnosis, and type of hospital (general or academic).
RESULTS: The mean annual frequency of visits to the ophthalmologist for patients with ocular hypertension and glaucoma was 2.43 and 3.74, respectively, and the mean cost per patient was $280 and $559, respectively. The mean cost of patients with glaucoma who had no changes in medication therapy was $347 and increased to $1,765 in patients with more than three adjustments in medication therapy. Outpatient visits to the ophthalmologist and medication contributed most to total costs. Regression analysis showed that costs were significantly related to intraocular pressure, diagnosis, severe excavation of the optic nerve head, and type of hospital.
CONCLUSIONS: The costs of patients with glaucoma were twice as high as the costs of patients with ocular hypertension. Aside from diagnosis, differences in costs between patients could partly be explained by baseline patient characteristics. Patients in academic hospitals had more severe glaucoma and treatment was considerably more expensive than for patients in nonacademic hospitals.

Entities:  

Mesh:

Year:  2001        PMID: 11442180     DOI: 10.1097/00061198-200106000-00007

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  12 in total

1.  Comparison of diurnal intraocular pressure control by latanoprost versus travoprost : results of an observational survey.

Authors:  Philippe Denis; Robert Launois; Marion Devaux; Gilles Berdeaux
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 2.  The economic burden of glaucoma and ocular hypertension: implications for patient management: a review.

Authors:  Jean-François Rouland; Gilles Berdeaux; Antoine Lafuma
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

3.  Direct cost and predictive factors for treatment in patients with ocular hypertension or early, moderate and advanced primary open-angle glaucoma: the CoGIS study in Germany.

Authors:  Katrin Lorenz; Christian Wolfram; Lusine Breitscheidel; Margarita Shlaen; Yves Verboven; Norbert Pfeiffer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-04-30       Impact factor: 3.117

Review 4.  The economic implications of glaucoma: a literature review.

Authors:  Jordana K Schmier; Michael T Halpern; Mechelle L Jones
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

5.  Longitudinal trends in resource use in an incident cohort of open-angle glaucoma patients: resource use in open-angle glaucoma.

Authors:  Joshua D Stein; Leslie M Niziol; David C Musch; Paul P Lee; Sameer V Kotak; Colleen M Peters; Steven M Kymes
Journal:  Am J Ophthalmol       Date:  2012-07-11       Impact factor: 5.258

6.  Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries.

Authors:  A Boonen; D van der Heijde; R Landewé; F Guillemin; M Rutten-van Mölken; M Dougados; H Mielants; K de Vlam; H van der Tempel; S Boesen; A Spoorenberg; H Schouten; Sj van der Linden
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

Review 7.  Cost of illness of glaucoma: a critical and systematic review.

Authors:  Richard G Fiscella; Jeff Lee; Elizabeth J H Davis; John Walt
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 8.  Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension.

Authors:  Greg L Plosker; Susan J Keam
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

9.  Medical outcomes of glaucoma therapy from a nationwide representative survey.

Authors:  Philippe Denis; Antoine Lafuma; Gilles Berdeaux
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

10.  Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France.

Authors:  Stéphanie Payet; Philippe Denis; Gilles Berdeaux; Robert Launois
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.